Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
By F. Bidard, D. Peeters, T. Fehm, F. Nolè, R. Gisbert-Criado, D. Mavroudis, S. Grisanti, D. Generali, J. García-Saenz, J. Stebbing and 33 more. The Lancet Oncology, 2014
779 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/099c54004704f6bb460b12c0a9fff91a5c552d72
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA (2015, background): “Another “liquid biopsy”method, circulating tumor cells (CTCs), may only be detectable in 30%–50% of patients with metastatic disease [42].”
- RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics (2015, neutral): “…evaluated as liquid biopsies, including plasma DNA (Bettegowda et al., 2014; Chan et al., 2013; Diehl et al., 2008; Murtaza et al., 2013; Newman et al., 2014; Thierry et al., 2014) and circulating tumor cells (Bidard et al., 2014; Dawson et al., 2013; Maheswaran et al., 2008; Rack et al., 2014).”
- Liquid biopsy: current technology and clinical applications (2022, background): “5 mL or higher at baseline on progression-free and overall survival [83].”
- Molecular profiling for precision cancer therapies (2020, background): “, CTC dynamics in prostate and breast cancer patients treated with chemotherapy) [61, 62], early detection of resistance mechanisms [63, 64], assessment of tumor burden (e.”